Moreover, the 36-month beta value for ELEV is 1.33. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ELEV is 52.02M and currently, short sellers hold a 12.39% of that float. On January 23, 2025, ELEV’s average trading volume was 1.92M shares.
ELEV) stock’s latest price update
Elevation Oncology Inc (NASDAQ: ELEV) has seen a decline in its stock price by -5.85 in relation to its previous close of 0.71. However, the company has experienced a -14.15% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-13 that — Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer — — Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 — — On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 — — Plan to present preclinical data for HER3 ADC EO-1022 in 1H 2025 and file an Investigational New Drug (IND) application in 2026 — BOSTON, Jan. 13, 2025 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones. “We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care,” said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
ELEV’s Market Performance
Elevation Oncology Inc (ELEV) has experienced a -14.15% fall in stock performance for the past week, with a 7.20% rise in the past month, and a 16.36% rise in the past quarter. The volatility ratio for the week is 10.53%, and the volatility levels for the past 30 days are at 13.60% for ELEV. The simple moving average for the past 20 days is 0.30% for ELEV’s stock, with a -62.66% simple moving average for the past 200 days.
Analysts’ Opinion of ELEV
Piper Sandler, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $10. The rating they have provided for ELEV stocks is “Overweight” according to the report published on May 31st, 2024.
Stephens gave a rating of “Overweight” to ELEV, setting the target price at $8 in the report published on May 14th of the previous year.
ELEV Trading at 4.60% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.51% of loss for the given period.
Volatility was left at 13.60%, however, over the last 30 days, the volatility rate increased by 10.53%, as shares surge +7.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.82% upper at present.
During the last 5 trading sessions, ELEV fell by -14.15%, which changed the moving average for the period of 200-days by -86.76% in comparison to the 20-day moving average, which settled at $0.6680. In addition, Elevation Oncology Inc saw 19.09% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ELEV
Current profitability levels for the company are sitting at:
- -724.26 for the present operating margin
- 0.5 for the gross margin
The net margin for Elevation Oncology Inc stands at -723.24. The total capital return value is set at -0.42. Equity return is now at value -63.67, with -40.67 for asset returns.
Based on Elevation Oncology Inc (ELEV), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.24. The debt to equity ratio resting at 0.45. The interest coverage ratio of the stock is -8.76.
Currently, EBITDA for the company is -41.47 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 386.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.77.
Conclusion
To wrap up, the performance of Elevation Oncology Inc (ELEV) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
